Geode Capital Management LLC Has $9.58 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Geode Capital Management LLC grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 16.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,199,056 shares of the company's stock after purchasing an additional 166,699 shares during the period. Geode Capital Management LLC owned about 2.24% of EyePoint Pharmaceuticals worth $9,583,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock valued at $82,000 after purchasing an additional 4,172 shares during the last quarter. Greenwich Wealth Management LLC bought a new position in EyePoint Pharmaceuticals during the second quarter valued at about $94,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of EyePoint Pharmaceuticals by 271.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company's stock worth $95,000 after buying an additional 7,953 shares during the last quarter. Cyndeo Wealth Partners LLC bought a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter worth about $100,000. Finally, Arizona State Retirement System increased its holdings in shares of EyePoint Pharmaceuticals by 9.7% during the 2nd quarter. Arizona State Retirement System now owns 13,251 shares of the company's stock valued at $115,000 after acquiring an additional 1,171 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on EYPT shares. Robert W. Baird reduced their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating for the company in a report on Monday, November 11th. Chardan Capital lifted their price target on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $18.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Saturday, September 21st. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat, EyePoint Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $25.71.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT traded up $0.58 during mid-day trading on Thursday, hitting $8.03. The company had a trading volume of 1,132,168 shares, compared to its average volume of 939,282. EyePoint Pharmaceuticals, Inc. has a 12 month low of $6.90 and a 12 month high of $30.99. The firm has a market cap of $548.06 million, a P/E ratio of -4.02 and a beta of 1.45. The business's 50-day simple moving average is $9.17 and its 200-day simple moving average is $8.98.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.